Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : GILD crawled time : 09:00 save search
Gilead Sciences to Present at Upcoming November 2023 Investor Conferences
Published: 2023-11-09 (Crawled : 09:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.47%
H: 0.23%
C: -3.29%
sciences
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-09-18 (Crawled : 09:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.25%
H: 0.38%
C: -0.32%
yescarta t-cell treatment response therapy study
Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
Published: 2023-06-14 (Crawled : 09:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.52%
H: 0.46%
C: -0.12%
liver disease association research study
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
Published: 2023-05-26 (Crawled : 09:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.45%
H: 0.79%
C: -1.17%
covid-19 veklury chmp renal positive dialysis
With Market Size Valued at $13.7 Billion by 2026, it`s a Healthy Outlook for the Global Angina Pectoris Drugs Market
Published: 2022-07-04 (Crawled : 09:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
GLAXF | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
| Email alert
Add to watchlist
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
| Email alert
Add to watchlist
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
| Email alert
Add to watchlist
market
Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
Published: 2021-05-17 (Crawled : 09:00) - prnewswire.com
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.07%
H: 1.71%
C: 0.86%
china cancer license breast cancer application
Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia
Published: 2021-03-11 (Crawled : 09:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.63%
H: 0.83%
C: -0.66%
covid trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.